Posts tagged treatment
Titan Pharma implant IND cleared for Parkinson’s study

The FDA has cleared an IND application by Titan Pharmaceuticals (NASDAQ:TTNP) for its ropinirole implant intended to treat the signs and symptoms of Parkinson's disease.

Read More
WB starts PTC Therapeutics at MP

William Blair initiated coverage of PTC Therapeutics (NASDAQ:PTCT) with a “market perform” rating, citing a possibly tough road ahead for approval of the company’s ataluren in the U.S. The stock closed at $17.72 on Aug. 22.

Read More
HCW starts Pharming at buy

H.C. Wainwright launched coverage of  Pharming Group NV (AEX:PHARM) with a “buy” rating and €1.50 price target. The stock was recently quoted at €0.45. 

Read More
HCW starts AzurRx at buy

H.C. Wainwright initiated coverage of AzurRx BioPharma (NASDAQ:AZRX) with a “buy” rating and $8 price target. The stock closed at $4.11 on July 24.

Read More
BioLight posts positive latanoprost insert data

BioLight Life Sciences (TASE:BOLT) announced successful results from its glaucoma insert, VS101, (Eye-D latanoprost) in a Phase 1/2a clinical trial, which demonstrated its ability to lower intraocular pressure (IOP) for a 12-week period, with a favorable safety profile.

Read More
Knight NDS for Probuphine in Canada accepted for review

Knight Therapeutics’ (TSX:GUD) New Drug Submission (NDS) for Probuphine, a subdermal implant of buprenorphine for the treatment of opioid drug dependence, has been accepted for review by Health Canada.

Read More
Ladenburg starts Reata at buy

Ladenburg Thalmann launched coverage of Reata Pharmaceuticals (NASDAQ:RETA) with a “buy” rating and price target of $55. The stock closed at $21.21 on April 12.

Read More
RepliCel posts positive RCS-01 interim results

RepliCel Life Sciences (OTCQB:REPCF; TSXV:RP; FRA:P6P2) reported statistically and clinically significant positive data from an interim analysis of its Phase I study evaluating RCS-01 for the treatment of aging and sun-damaged skin.

Read More
RepliCel hair loss trial meets primary endpoints

RepliCel Life Sciences (OTCQB:REPCF; TSXV:RP; FRA:P6P2) has successfully completed its first-in-human clinical study of the company's autologous cell therapy for the treatment of androgenetic alopecia (pattern baldness).

Read More
Aurinia plans single Phase 3 trial of voclosporin in LN

Aurinia Pharmaceuticals (NASDAQ:AUPH; TSX:AUP) plans to initiate a single Phase 3 clinical trial (Aurora), with a design consistent with that of the continuing Aura-LV clinical trial of voclosporin for the treatment of lupus nephritis (LN).

Read More
HCW starts OSE Immunotherapeutics at buy

H.C. Wainwright initiated coverage of OSE Immunotherapeutics (ISIN: FR0012127173; Mnémo: OSE) with a “buy” rating and a 12-month price target of €12.00. The stock closed at €6.25 on March 6.

Read More
3DS to present positive results for prostate cancer liquid biopsy

Dr. Sabine Mai, a co-founder and principle inventor of 3D Signatures (TSX-V:DXD; OTCQB:TDSGF; FSE:3D0), will present on Feb. 21 at the International Molecular Medicine Tri-Conference in San Francisco, results of a prospective blood-based prostate cancer pilot study using the company’s TeloView software platform.

Read More
Ladenburg starts Albireo Pharma at buy

Ladenburg Thalmann initiated coverage of Albireo Pharma (NASDAQ:ALBO) with a “buy” rating and $40 price target. The stock closed at $20.28 on Feb. 15.

Read More
Benefits of Titan’s Probuphine featured in DDBN

Drug Deliver Business News has carried an article about Titan Pharmaceuticals (NASDAQ:TTNP) and its Probuphine implant, the first marketed product to provide maintenance treatment for opioid addiction continuously for six months following a single administration procedure.

Read More
Maxim raises Ritter Pharma price target to $5

Maxim Group raised its price target for Ritter Pharmaceuticals (NASDAQ:RTTR) to $5 from $4 ahead of top-line data in the current quarter for a Phase 2b/3 study of RP-G28 for the treatment of lactose intolerance. The stock closed at $3.49 on Feb. 13.

Read More
HCW starts Bellerophon Therapeutics at buy

H.C. Wainwright initiated coverage of Bellerophon Therapeutics (NASDAQ:BLPH) with a “buy” rating and price target of $5. The stock closed at 67 cents on Jan. 20.

Read More
Profound Medical COO joins XOR-Labs board

Steven Plymale, president and COO of Profound Medical (TSX-V:PRN), has been appointed an independent director of XOR-Labs, a spinoff from Toronto General Hospital at University Health Network, the world's leading center for lung transplantation and a MaRS Innovation company.

Read More
BTIG starts CoLucid Pharma at buy

BTIG initiated coverage of CoLucid Pharmaceuticals (NASDAQ:CLCD) with a “buy” rating and $58 price target, calling the company’s Lasmiditan drug candidate a game changer in acute migraine. The stock closed at $36.16 on Dec 21.

Read More
HCW starts Cidara Therapeutics at buy

H.C. Wainwright launched coverage of Cidara Therapeutics (NASDAQ:CDTX) with a “buy” rating and $25 price target. The stock closed at $10.80 on Dec. 16.

Read More